The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension
Open accessAbstract
Rationale: Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output. To compensate, neurohormonal systems such as the renin–angiotensin–aldosterone system (RAAS) and the sympathetic nervous system are up-regulated, but this may have long-term negative effects on the progression of iPAH. Objectives: Assess systemic and pulmonary RAAS activity in patients with iPAH and determine the efficacy of chronic RAAS inhibition in experimental PAH. Methods: We collected 79 blood samples from 58 patients with iPAH in the VU University Medical Center Amsterdam (between 2004 and 2010) to determine systemic RAAS activity. Measurements and Main Results: We observed increased levels of renin, angiotensin (Ang)I, and AngII, which were associated with disease progression (P < 0.05) and mortality (P < 0.05). To determine pulmonary RAAS activity, lung specimens were obtained from patients with iPAH (during lung transplantation, n = 13) and control subjects (during lobectomy or pneumonectomy for cancer, n = 14). Local RAAS activity in pulmonary arteries of patients with iPAH was increased, demonstrated by elevated angiotensin-converting enzyme activity in pulmonary endothelial cells and increased AngII type 1 (AT1) receptor expression and signaling. In addition, local RAAS up-regulation was associated with increased pulmonary artery smooth muscle cell proliferation via enhanced AT1 receptor signaling in patients with iPAH compared with control subjects. Finally, to determine the therapeutic potential of RAAS activity, we assessed the chronic effects of an AT1 receptor antagonist (losartan) in the monocrotaline PAH rat model (60 mg/kg). Losartan delayed disease progression, decreased right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular–arterial coupling in rats with PAH. Conclusions: Systemic and pulmonary RAAS activities are increased in patients with iPAH and are associated with increased pulmonary vascular remodeling. Chronic inhibition of RAAS by losartan is beneficial in experimental PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is some concern regarding the malignant potential of buloxibutid given the association of increased MMP-13 levels in several cancers [130–134].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Self-citationvan de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Self-citationAngiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Eichhorn, E. J., & Bristow, M. R. (1996) · Circulation · doi:10.1161/01.cir.94.9.2285 · Cited by 468
Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension
Velez-Roa, S., Ciarka, A., Najem, B., Vachiery, J.-L., Naeije, R., & van de Borne, P. (2004) · Circulation · doi:10.1161/01.cir.0000140724.90898.d3 · Cited by 443
Angiotensin II Signaling in Vascular Smooth Muscle: New Concepts
Griendling, K. K., Ushio-Fukai, M., Lassègue, B., & Alexander, R. W. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.366 · Cited by 407
Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy
Bader, M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105610 · Cited by 345
Nootens, M., Kaufmann, E., Rector, T., Toher, C., Judd, D., Francis, G. S., & Rich, S. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00399-1 · Cited by 317
Cited by
Khan, A., Benthin, C., Zeno, B., Albertson, T. E., Boyd, J., Christie, J. D., Hall, R., Poirier, G., Ronco, J. J., Tidswell, M., et al. (2017) · Critical Care · doi:10.1186/s13054-017-1823-x · Cited by 602
Gorter, T. M., van Veldhuisen, D. J., Bauersachs, J., Borlaug, B. A., Celutkiene, J., Coats, A. J. S., Crespo-Leiro, M. G., Guazzi, M., Harjola, V.-P., Heymans, S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1029 · Cited by 389
Management of Pulmonary Arterial Hypertension
McLaughlin, V. V., Shah, S. J., Souza, R., & Humbert, M. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.540 · Cited by 366
Self-citationRight Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension
Rain, S., Handoko, M. L., Trip, P., Gan, C. T.-J., Westerhof, N., Stienen, G. J., Paulus, W. J., Ottenheijm, C. A. C., Marcus, J. T., Dorfmüller, P., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001873 · Cited by 363
Self-citationAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
Humbert, M., Lau, E. M. T., Montani, D., Jaïs, X., Sitbon, O., & Simonneau, G. (2014) · Circulation · doi:10.1161/circulationaha.114.006974 · Cited by 342
Self-citation
Metadata
- Authors
- de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., François, C., Schalij, I., Dorfmüller, P., Simonneau, G., Fadel, E., Perros, F., Boonstra, A., Postmus, P. E., van der Velden, J., Vonk-Noordegraaf, A., Humbert, M., Eddahibi, S., & Guignabert, C.
- Affiliations
- INSERM UMR 999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France
- Université Paris-Sud (FR)
- Amsterdam Cardiovascular Sciences (NL)
- Department of Pulmonology and
- Department of Physiology, VU University Medical Center/Institute of Cardiovascular Research, Amsterdam, The Netherlands; and
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10
- Volume
- 186
- Issue
- 8
- Pages
- 780-789
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5104838
- OpenAlex
- W2156240908
- Cited by
- 346
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 16 · 2023: 25 · 2022: 21 · 2021: 42 · 2020: 33 · 2019: 25 · 2018: 29 · 2017: 16 · 2016: 21 · 2015: 34 · 2014: 26 · 2013: 28 · 2012: 7
- FWCI
- 24.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Respiratory Society
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Keywords
- idiopathic pulmonary arterial hypertension, renin-angiotensin-aldosterone system, angiotensin II type 1 receptor, angiotensin-converting enzyme, pulmonary vascular remodeling, losartan, monocrotaline-induced pulmonary hypertension, right ventricular afterload, right ventricular-arterial coupling, disease progression, mortality, angiotensin I, angiotensin II
- MeSH terms
- Animals, Cells, Cultured, Endothelium, Vascular, Female, Humans, Hypertension, Pulmonary, Male, Middle Aged, Renin-Angiotensin System, Up-Regulation, Proportional Hazards Models, Case-Control Studies, Monocrotaline, Disease Progression, Losartan, Myocytes, Smooth Muscle, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Rats, Familial Primary Pulmonary Hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1164/rccm.201203-0411oc
- The paper
- de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., François, C., Schalij, I., Dorfmüller, P., Simonneau, G., Fadel, E., Perros, F., Boonstra, A., Postmus, P. E., van der Velden, J., Vonk-Noordegraaf, A., Humbert, M., Eddahibi, S., & Guignabert, C. (2012). Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201203-0411oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.